In the single-arm, multicentre trial, each participant will receive a 75mg dose of UGN-103 through intravesical instillation once a week for six weeks. The drug’s efficacy will be assessed based ...

Reproxalap was safe and well-tolerated, with mild instillation site discomfort as the most common adverse event. The topical ocular drug is an investigational new drug candidate that requires more ...